Derma Pharma Pty Ltd (Derma Pharma) is a specialty pharmaceutical company with a focus on bridging gaps in the treatment of the top 3 most prevalent skin diseases globally – acne, psoriasis and eczema.

​​

Gaps in the acne, psoriasis, and eczema markets remain unaddressed, creating a vital

opportunity for innovation.

​

Core Focus: Addressing unmet medical needs in dermatological conditions, initially targeting acne, which affects 9.4% of the global population. An acne range will be launched in Q1 Year 2 in the Australian/New Zealand markets followed by the USA, Europe, and Japan. 

Future skin solutions will be focused on psoriasis and eczema.

​

Innovative Technology: Leveraging our proprietary ALGAVIO ingredient to innovate and revolutionize acne treatments. Acne ranks as the eighth most prevalent disease worldwide, offering a significant market opportunity. Psoriasis and eczema products will follow the successful launch of the acne range.

"ALGAVIO innovates and revolutionises acne treatments."

Mission: We are redefining dermatology with next-generation, science-led skincare that prioritises safety, efficacy, and sustainability.

Our Breakthrough: Algavio™ is the result of years of research and biotech innovation, delivering a safe, non-toxic solution to chronic skin conditions including acne, eczema, and psoriasis.

Our Vision: To create a global skin health platform with patented, evidence-based actives that improve lives and challenge the status quo of dermatological care.

​

Capital Raise and Exit Strategy

Derma Pharma is conducting a Seed Round raising $USD2M via a SAFE instrument. Funds will be used to conduct the necessary Research & Development to test and formulate the initial acne range and develop the market entry strategy.

 

We plan to build the business to a stage where a Trade Sale or an IPO on either the ASX, TSX or AIM is possible within a 4 – 5 year period.